3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Cyclophosphamide
35
Temozolomide
33
Filgrastim
26
Etoposide
26
Carboplatin
25
Vincristine
22
Cisplatin
22
Radiotherapy
20
Magnetic Resonance Spectroscopy
18
Thiotepa
14
Irinotecan
13
Granulocyte Colony-Stimulating Factor
12
Peripheral Blood Stem Cell Transplantation
11
Lomustine
11
Specimen Handling
9
Radiation
9
Melphalan
9
etoposide phosphate
8
Topotecan
8
Methotrexate
8
X-Rays
7
Platinum
7
Phantoms, Imaging
7
sonidegib
6
Biopsy
6
1,2-diaminocyclohexaneplatinum II citrate
6
sargramostim
5
palbociclib
5
Nuclear Medicine Department, Hospital
5
HhAntag691
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts